Drug Discovery
ByIs Partnership-Led Innovation Replacing M&A in Oncology? BMS and Janux Strike $850 Million T-Cell Engager Deal
22 January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Janux Therapeutics,…
Can Global Partnerships Future-Proof Epidemic Preparedness? SK bioscience, Merck (MSD), and Hilleman Unite to Strengthen Ebola Vaccine Supply
23 January 2026 Executive Summary A global vaccine partnership has been established between SK bioscience, MSD (Merck &…
Is Strategic Out-Licensing the Fastest Path to Global Scale? Restari Secures $230 Million PDE-5 Deal with AriBio
23 January 2026 Executive Summary Restari has secured exclusive global out-licensing rights from AriBio for a next-generation PDE-5…
Is GSK Buying Its Way Past the Patent Cliff? $2.2 Billion Rapt Therapeutics Deal Signals Pipeline Reset
January 2026 Executive Summary GSK has agreed to acquire Rapt Therapeutics, a U.S.-based biotech focused on inflammatory and…
Why Is Roche Returning to China for Its Next Antibody-Drug Conjugate Bet?
January 2026 – Strategic Partnerships | China Biopharma | Oncology & ADCs Roche has extended its collaboration with…
Roche Signals Dual Growth Strategy: Price Reform Alignment in the U.S. and Aggressive Expansion Across Oncology and Obesity
January 2026 | Pharma & Policy | Bloomberg Interview Insight Roche is positioning itself for its next growth…
